A computer-implemented method for predicting future operating conditions of a healthcare laboratory is provided. The healthcare laboratory contains one or more in-vitro diagnostic laboratory instruments configured to process medical samples. The method comprises: receiving medical sample event data describing events relating to one or more medical samples to be processed by the laboratory, augmenting the medical sample event data with laboratory data; creating a feature set from the augmented medical sample event data, the feature set including time bracketed data derived from the augmented medical sample event data; using the feature set as an input for a trained machine learning model, the machine learning model having been trained on historical feature sets to predict a future medical sample events within a forecast time range; and receiving, from the trained machine learning model, a prediction of future medical sample events for the forecast time range as an output.
G16H 40/20 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour la gestion ou l’administration de ressources ou d’établissements de soins de santé, p. ex. pour la gestion du personnel hospitalier ou de salles d’opération
G06Q 10/04 - Prévision ou optimisation spécialement adaptées à des fins administratives ou de gestion, p. ex. programmation linéaire ou "problème d’optimisation des stocks"
G16H 10/40 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données relatives aux analyses de laboratoire, p. ex. pour des analyses d’échantillon de patient
The invention relates to novel compounds having the general formula Ib
The invention relates to novel compounds having the general formula Ib
The invention relates to novel compounds having the general formula Ib
wherein R1, R2, R3, R4, R5 and Z are as described herein, composition including the compounds and methods of using the compounds.
C07D 401/12 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 253/07 - Triazines-1, 2, 4 comportant trois liaisons doubles entre chaînons cycliques ou entre chaînons cycliques et chaînons non cycliques avec des hétéro-atomes ou des atomes de carbone comportant trois liaisons à des hétéro-atomes, avec au plus une liaison à un halogène, p. ex. radicaux ester ou nitrile, liés directement aux atomes de carbone du cycle
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
The present invention concerns treatment of previously untreated HER2-positive metastatic breast cancer with a combination of a growth inhibitory HER2 antibody, a HER2 dimerization inhibitor antibody and a taxane. In particular, the invention concerns the treatment of HER2-positiv metastatic breast cancer in patients who did not receive prior chemotherapy or biologic therapy with a HER2 antibody binding essentially to epitope 2C4, a HER2 antibody binding essentially to epitope 4D5, and a taxane. The invention further comprises extending survival of such patients by the combination therapy of the present invention. In a preferred embodiment, the treatment involves administration of trastuzumab, pertuzumab and docetaxel.
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
A61K 31/337 - Composés hétérocycliques ayant l'oxygène comme seul hétéro-atome d'un cycle, p. ex. fungichromine ayant des cycles à quatre chaînons, p. ex. taxol
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/32 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des produits de traduction des oncogènes
4.
RAMAN-based method for the differentiation of AAV particle serotype and AAV particle loading status
Herein is reported a method for determining in an aqueous sample using RAMAN spectroscopy viral particles with encapsidated nucleic acids comprising the steps of providing a sample and irradiating the sample with a light source; measuring the total intensity of RAMAN scattered light of each one of a first plurality of pre-selected wavenumbers and/or wavenumber ranges to obtain a first data set for the sample; performing a first set of mathematical data processing steps on the first data set; and determining the viral particles with encapsidated nucleic acid in the sample based upon the output of the first set of mathematical data processing steps, wherein the first set of mathematical data processing steps comprises a principal component analysis and the determining is based on the first principal component.
The present invention relates to systems and methods to optimize a supply chain. Various embodiments of the present invention relate to systems and methods to optimize a multi-distribution-level supply chain and, more specifically but not limited, to systems and methods to optimize a multi-distribution-level supply chain via a machine-learning model based on reinforcement learning.
In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C-L1-Z-(L2)p-X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1.
In a first aspect, the invention relates to a derivatisation agent, preferably derivatisation agent for analytes intended to be analysed via LDI-MS, comprising a structural element of formula (I) C-L1-Z-(L2)p-X, wherein C is a chromophore having an absorption maximum in the range of from 280 to 400 nm; Z is a charged unit comprising at least one permanently charged moiety; X is a reactive group; L1, L2 are each a linker unit; and p is either zero or 1.
A second aspect of the invention is related to a kit comprising the derivatisation agent according to the first aspect. In a third aspect, the invention is directed to a use of the derivatisation agent according to the first aspect for the mass spectrometric determination of an analyte molecule, wherein the mass spectrometric determination is LDI-MS. A fourth aspect of the invention relates to a conjugate of a derivatisation agent according to the first aspect and an analyte, wherein the conjugate has the structure of formula (II) C-L1-Z-(L2)p-Xa-Ya-A, wherein C, L1, L2, p, Z and N are as defined in the context of the first aspect; Xa is a remainder of a reactive group X as defined in the context of the first aspect; A is the analyte and Ya is the remainder of a reactive group Y bound to the analyte A, which has reacted with the reactive group X of the derivatisation agent thus forming a covalent bound between Xa and Ya. A fifth aspect of the invention is related to a method for the mass spectrometric determination of an analyte molecule comprising the steps: (a) providing an analyte of interest; (b) providing a derivatisation agent comprising a structure of formula (I) as defined in the context of the first aspect; (c) reacting the analyte provided according to (a) with the derivatisation agent provided according to (b), whereby a conjugate of the analyte and the derivatisation agent is formed, and (d) subjecting the conjugate formed in (c) to a mass spectrometric analysis, wherein the mass spectrometric analysis is preferably LDI-MS.
G01N 33/74 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des hormones
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
The invention provides a compound represented by represented by the following structural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A sampling device (110) for sampling bodily fluid is proposed, comprising a stationary component (118) and a movable component (120) being movably mounted to the stationary component (118). The movable component (120) is movable from at least one distal position to at least one proximal position and back. The movable component (120) comprises at least one penetration element (132) for penetrating the skin of a user, which, in the distal position of the movable component (120), is received within the stationary component (118) and which, in the proximal position of the movable component (120), protrudes from an application side (128) of the stationary component (118). The movable component (120) comprises a container receptacle (134) for receiving at least one sample container (114) having a septum (136). The sampling device (110) further comprises a sample collection channel (138) for transporting sample from the application side (128) into the container receptacle (134). The sampling device (110) further comprises a pressure chamber (140) having a volume being dependent on the position of the movable component (120), wherein the volume when the movable component (120) is in the proximal position is smaller than the volume when the movable component (120) is in the distal position. The sampling device (110) further comprises a pressure adjustment channel (154) for transferring underpressure from the pressure chamber (140) into the sample container (114) through the septum (136) when the movable component (120) is retracted from the proximal position into the distal position. Further, a sampling kit (112) for sampling bodily fluid and a method for generating an underpressure in a sample container (114) having a septum (136) are proposed.
A61B 5/15 - Dispositifs de prélèvement d'échantillons de sang
A61B 5/151 - Dispositifs de prélèvement d'échantillons de sang spécialement adaptés pour le prélèvement d'échantillons de sang capillaire, p. ex. par des lancettes
9.
SYSTEMS AND METHODS FOR MINIMUM RESIDUAL DISEASE (MRD) DETECTION
The disclosure is related to using machine learning algorithms to detect minimum residual disease (MRD) in cancer patients. For example, a method includes detecting somatic variants from pre-treatment samples from a patient using a variant caller. The method also includes filtering any germline mutations and sequencing artifacts from the detected somatic mutations. The method also includes classifying sequencing reads covering remaining somatic variants from the filtering using a machine learning model to identify somatic variants used for minimum residual disease (MRD) detection. The machine learning model may be trained using a random forest classifier based on a plurality of features. The method also includes analyzing the identified somatic variants to determine whether the patient is positive or negative for MRD.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
The present invention generally relates to antibodies that bind to CD3 and CD19, e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
The invention provides a compound represented by represented by the following strutural formula:
or a pharmaceutically acceptable salt, or a stereoisomer thereof useful for treating cancer.
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
C07D 401/14 - Composés hétérocycliques contenant plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle, au moins un cycle étant un cycle à six chaînons avec un unique atome d'azote contenant au moins trois hétérocycles
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/4439 - Pyridines non condenséesLeurs dérivés hydrogénés contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. oméprazole
A61K 31/4745 - QuinoléinesIsoquinoléines condensées en ortho ou en péri avec des systèmes hétérocycliques condensées avec des systèmes cycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. phénanthrolines
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
A61K 31/55 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole
A61K 31/553 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à sept chaînons, p. ex. azélastine, pentylènetétrazole ayant au moins un azote et au moins un oxygène comme hétéro-atomes d'un cycle, p. ex. loxapine, staurosporine
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention generally relates to antibodies that bind to CD3, including multispecific antibodies e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
09 - Appareils et instruments scientifiques et électriques
Produits et services
Bio-sensors; biochip sensors; barcode readers; bar code
printers; portable scanners; radio-frequency identification
(RFID) tags; interfaces for computers; electronic docking
stations; application software for cloud computing services;
cases for tablet computers; cases for data storage devices;
computer software relating to the medical field; computer
software for use in medical decision support systems;
workflow management system software; software as a medical
device [SaMD], downloadable; application software for mobile
devices.
Herein is reported an immunoassay for quantifying the amount of anti-drug antibody, which anti-drug antibody can specifically bind to a drug antibody, which drug antibody can specifically bind to a therapeutic target, in a scrum or plasma sample comprising the steps of a) incubating the serum or plasma sample at a pH value that is about the pI value of the target, and optionally removing formed precipitate after the incubation, b) incubating the serum or plasma sample obtained in step a) at a pHI value of about 2, and optionally centrifuging the incubated sample to remove formed precipitate, c) adjusting the pH value to about 7.4, adding capture antibody conjugated to a first member of a binding pair and tracer antibody conjugated to a detectable label to the serum or plasma sample obtained in step b) and incubating the mixture to form a capture antibody-anti-drug antibody-tracer antibody-complex, d) quantifying the complex formed in step c) and thereby quantifying the amount of anti-drug antibody in the serum or plasma sample.
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
16.
APPARATUS FOR AND METHOD IN DIRECT DRUG INFUSION USING A LABEL AS A HANGER
An apparatus and method for direct drug infusion from a vial to a patient are provided. A movable hanger label is provided to adhere to and support the vial to facilitate direct infusion of a drug, such as one or more pharmaceuticals, biopharmaceuticals, and/or biologics, from the vial to the patient. Additionally, a process is provided in which the drug, contained in the vial with the movable hanger label, may be directly infused through a primed infusion line with a rapid infusion rate. A saline flush is incorporated at the end of the administration to flush the infusion line, resulting in a reduced amount of the drug remaining in the line.
The present disclosure provides methods for combinatorial indexing of nucleic acids of single cells or nuclei. In particular, the methods of the present disclosure result in the incorporation of at least two index sequences within the nucleic acids of single cells or nuclei. The present disclosure further provides methods for generating and sequencing libraries of such indexed nucleic acids.
The present invention relates to methods for monitoring a subject who has been diagnosed as having or likely to have neurological motor disease or disorder, the method comprising: obtaining a pose derived from movement data comprising joint location data for a plurality of joints of the subject while performing a balance test; and determining the cosine similarity between the pose derived from the movement data and a reference pose derived from reference movement data, wherein said cosine similarity is indicative of the presence and/or severity of a neurological motor disease or disorder Related systems and clinical methods are also described.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
The invention provides compounds having the general formula (I) wherein A, X1, X2, R1, R2, R3, R4, and R5 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
C07D 405/14 - Composés hétérocycliques contenant à la fois un ou plusieurs hétérocycles comportant des atomes d'oxygène comme uniques hétéro-atomes du cycle et un ou plusieurs hétérocycles comportant des atomes d'azote comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61K 31/4985 - Pyrazines ou pipérazines condensées en ortho ou en péri avec des systèmes hétérocycliques
20.
A DIGITAL MOTOR SCORE FOR SENSITIVE DETECTION OF HUNTINGTON'S DISEASE
The present invention relates to the field of diagnostics. Specifically, it relates to a computer-implemented method for assessing Huntington's disease (HD) in a subject comprising the steps of determining a Huntington's disease digital motor score (HDDMS) based on a multitude of digital performance features derived from at least one or more of the following: accelerometer measurements, touch sensor measurements, and/or measurements of time, in a dataset of fine motoric and motoric activity measurements from said subject; comparing the determined HDDMS to a reference; and assessing HD in the subject based on said comparison. Further, the invention contemplates a device and a system for carrying out the afore-mentioned methods and the use of such device or system for assessing Huntington's disease in the subject.
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
A61B 5/11 - Mesure du mouvement du corps entier ou de parties de celui-ci, p. ex. tremblement de la tête ou des mains ou mobilité d'un membre
A61B 5/00 - Mesure servant à établir un diagnostic Identification des individus
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 498/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle dans lesquels le système condensé contient au moins quatre hétérocycles
22.
SELECTION OF DIVERSE CANDIDATE PEPTIDES FOR PEPTIDE THERAPEUTICS
A method for developing a therapeutic such as, for example, a peptide vaccine. A machine learning model is trained using a metric learning algorithm, training peptide sequence data, and training allele presentation data corresponding to the training peptide sequence data. Peptide sequence data identifying peptide sequences that correspond to peptides is received. A peptide sequence vector is generated, via a machine learning model, for each peptide sequence using the peptide sequence data to form a plurality of peptide sequence vectors. An output is generated using the plurality of peptide sequence vectors. The output provides an indication of similarity between peptide sequences of the plurality of peptide sequences. A group of candidate peptides is selected from the plurality of peptides for development of the therapeutic based on the output such that the group of candidate peptides includes at least two dissimilar candidate peptides.
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
The present invention relates to novel antibodies which bind to antigens on target cells, such as tumor cells, and which target radionuclides to said cells, to uses of those antibodies as well as methods of making them.
A61K 51/10 - Anticorps ou immunoglobulinesLeurs fragments
C07K 16/30 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire provenant de cellules de tumeurs
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
24.
CONDENSED PYRAZINES OR PYRIMIDINES ALS TREM2 AGOONISTS
The invention provides compounds having the general formula (I) or (II) (I) (II) wherein A, A1, X1, R1, R2, R3, R4, R5, and R6 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds in the treatment or prevention of diseases that are associated with TREM2.
A61K 31/4375 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'azote comme hétéro-atome du cycle, p. ex. quinolizines, naphtyridines, berbérine, vincamine
A61K 31/5025 - PyridazinesPyridazines hydrogénées condensées en ortho ou en péri avec des systèmes hétérocycliques
A61P 25/28 - Médicaments pour le traitement des troubles du système nerveux des troubles dégénératifs du système nerveux central, p. ex. agents nootropes, activateurs de la cognition, médicaments pour traiter la maladie d'Alzheimer ou d'autres formes de démence
A61P 29/00 - Agents analgésiques, antipyrétiques ou anti-inflammatoires non centraux, p. ex. agents antirhumatismauxMédicaments anti-inflammatoires non stéroïdiens [AINS]
Described herein are techniques of automatically extracting intervention responses of a subject from data associated with the subject. The system automatically determines time points (e.g., dates) indicating periods in which intervention responses were determined for subjects, and then uses the time points to identify datasets from which to extract intervention responses. The system extracts intervention responses of the subject from the identified datasets.
G16H 10/20 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des essais ou des questionnaires cliniques électroniques
G16H 15/00 - TIC spécialement adaptées aux rapports médicaux, p. ex. leur création ou leur transmission
G16H 30/20 - TIC spécialement adaptées au maniement ou au traitement d’images médicales pour le maniement d’images médicales, p. ex. DICOM, HL7 ou PACS
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
09 - Appareils et instruments scientifiques et électriques
10 - Appareils et instruments médicaux
Produits et services
Chemical, biochemical and biological preparations for scientific and research purposes, namely, diagnostic and detection reagents for scientific and research purposes; chemical reagents for research or laboratory use, other than for medical or veterinary use; chemical reagents for the preparation and staining of tissue specimens for research purposes; chemical reagents for non-medical purposes, namely, for use in histological and cytological tissue processing Chemical, biochemical and biological preparations for medical purposes, namely, diagnostic and detection reagents for medical use; in vitro diagnostic reagents for medical use; histology and cytology reagents and staining dyes for preparation and staining of tissue specimens for medical purposes; diagnostic reagents for medical use in the fields of pathology, immunohistochemistry and in situ-hybridization Scientific apparatus, equipment and instruments for performing analyses in laboratories, namely, automated slide staining apparatus for treating and staining tissue slide specimens for laboratory or research use; laboratory equipment, namely, automated sample handling equipment for treating and staining tissue slide specimens for diagnostic use for laboratory or research use; automated laboratory instruments, namely, slide scanners, digital imaging apparatus, microscopes and computer systems comprised of computer hardware and downloadable computer software, all for staining and visualization of tissue or cell based samples for research and scientific use; downloadable computer software for medical and diagnostic purposes, namely, for diagnosing medical disorders; downloadable computer software for the provision of automated diagnostic laboratory processes; downloadable computer software for use with laboratory instruments, namely, for use in providing remote automated control, connection, data analysis, and data management; computer systems comprised of computer hardware and downloadable software for collecting, storing, analyzing and reporting biological information, and for sample tracking and managing projects, laboratory workflow and data, for use in the fields of scientific, diagnostic and clinical research and for clinical diagnostic purposes; downloadable bioinformatics-enabled medical diagnosis software Medical apparatus and instruments for medical purposes, namely, automated slide staining apparatus for treating and staining tissue specimens for cancer and other tissue-based medical diagnostic testing; diagnostic apparatus for medical purposes, namely, sample preparation device for cancer and other tissue-based medical diagnostic testing; medical apparatus for performing in-vitro diagnostic tests for cancer and other tissue-based diseases; automated slide preparation and staining apparatus for use with tissue slide specimens for medical diagnostic use; medical apparatus and instruments for performing histological and cytological tissue processing and staining for diagnostic purposes
The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist.
The present invention provides a drug for treating or preventing cancer, the drug comprising a compound represented by the following formula (1), a salt thereof or a solvate thereof and being used in combination with a molecular-targeted agent, wherein the molecular-targeted agent is at least one member selected from the group consisting of a KRAS-G12C selective inhibitor, a SHP2 inhibitor, a VEGF inhibitor and a PD-1 axis binding antagonist.
C07K 16/22 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des facteurs de croissance
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The present invention is directed to pharmaceutical combinations for treating hepatitis B virus (HBV) infection comprising administering at least two, preferably two or three, different HBV therapeutics. In particular, the present invention relates to pharmaceutical combinations comprising an RNAi oligonucleotide targeting HBV and an anti-PDL1 antisense oligonucleotide.
A test carrier system (182) is disclosed. The test carrier system (182) comprises: at least one reaction and measurement cup (184), wherein the reaction and measurement cup (184) is configured for receiving at least one buffer solution (186), wherein the reaction and measurement cup (184) comprises at least one optical window (190) which is received in at least one wall (192) of the reaction and measurement cup (184), the optical window (192) enabling optical analysis of the buffer solution (186); and at least one sample processing unit (110), wherein the sample processing unit (110) is attachable to the reaction and measurement cup (184), wherein the sample processing unit (110) comprises: at least one sample application area (112), wherein the sample application area (112) is configured for receiving at least one sample, wherein the sample application area (112) comprises at least one capillary (114) which opens into an interior space (116) of the sample processing unit (110); and at least one chemical reagent (194), wherein the chemical reagent is received within the interior space (116) of the sample processing unit (110) or within the reaction and measurement cup (184); wherein the test carrier system (182) is configured to be rotatable around a rotation axis (196) of the test carrier system (182) whereby the buffer solution (186) is alternatively transportable to the sample application area (112) or to the chemical reagent (194) depending on at least one of a direction of rotation and a degree of rotation of the test carrier system (182) around the rotation axis (196) of the test carrier system (182).
A system and method for automated synthesis of a macromolecule from a nucleic acid template is provided, which includes a flow cell with a sipper, a mount with a thermal block, a pump, a selectable valve, a holder, an XYZ gantry, and a controller. The flow cell can be held in a fixed position while the gantry can move the holder to sippers of the flow cell. In this configuration, the sipper length can be reduced or minimized to reduce loss of precious reagents and the synthesized macromolecule.
The present invention relates to the treatment of PD-L1 -positive pancreatic cancer, e.g., PD-L1-positive pancreatic ductal adenocarcinoma (PDAC), e.g., PD-L1 -positive metastatic PDAC. More specifically, the invention pertains to the treatment of patients having a PD-L1 -positive pancreatic cancer by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody, e.g., by administering an anti-TIGIT antagonist antibody and an anti-PD-L1 antagonist antibody in combination with one or more chemotherapeutic agents.
A61K 31/00 - Préparations médicinales contenant des ingrédients actifs organiques
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
The invention is directed to a method for determining amino acid sequence mutations in a produced polypeptide, comprising the following steps of a) providing a sample of a produced polypeptide, b) incubating the polypeptide in the sample with a protease, c) performing a two dimensional analysis using reversed phase chromatography coupled with a high resolution mass spectroscopy (FT-ICR/FT-orbitrap) and MS/MS analysis of the amino acid sequence fragments of the peptides, d) data evaluation by comparing the LC-MS data sets obtained for the samples side by side with the data set of a reference sample, by searching for differences in the signal intensities at given retention times and by evaluation of differential signals with respect to amino acid sequence mutations. The reference sample for data evaluation (d) can be either a well characterized standard or one of the samples to be analyzed.
C12Q 1/37 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir une hydrolase faisant intervenir une peptidase ou une protéinase
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
33.
ESTIMATING THE ACCURACY OF AUTOMATICALLY TRANSCRIBED SPEECH WITH PRONUNCIATION IMPAIRMENTS
Systems and computer-implemented methods for determining an accuracy of automatically transcribed pathological speech comprise recording speech from a person to obtain an original speech recording; combining a perturbation with the original speech recording to obtain a perturbed speech recording; performing automatic speech recognition, ASR, on the original speech recording to obtain a first transcript; performing automatic speech recognition on the perturbed speech recording to obtain a second transcript; comparing the first transcript with the second transcript to quantify a mismatch between the first transcript and the second transcript.
The disclosure is in part directed to crystalline forms of 5-(3,4-dichlorophenyl)-N-((1R,2R)-2-hydroxycyclohexyl)-6-(2,2,2-trifluoroethoxy)nicotinamide and pharmaceutical compositions thereof.
Herein is reported a method for lysing recombinant AAV particle producing mammalian cells comprising the step of bringing a mammalian cell cultivation broth in contact with an alkyl polyglucoside detergent, preferably Triton CG 110, and thereby lysing recombinant AAV particle producing mammalian cells and releasing the produced recombinant AAV particles, wherein the mammalian cell cultivation broth comprises cultivated recombinant AAV particle producing mammalian cells and the cultivation medium used for the cultivation of said recombinant AAV particle producing mammalian cells (spent medium).
The invention provides methods of dosing for the treatment of cancers, such as multiple myelomas, with anti-fragment crystallizable receptor-like 5 (FcRH5)/anti-cluster of differentiation 3 (CD3) bispecific antibodies and lenalidomide.
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/454 - Pipéridines non condensées, p. ex. pipérocaïne contenant d'autres systèmes hétérocycliques contenant un cycle à cinq chaînons avec l'azote comme hétéro-atome du cycle, p. ex. pimozide, dompéridone
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Herein is reported a method for selecting a variant of a parental antibody variable domain encoding nucleic acid, wherein the parental antibody variable domain amino acid sequence encoded by said encoding nucleic acid has at least one developability hot spot, the method comprising the steps of (i) providing a multitude of DNA-containing samples (genomic material of antibody secreting B-cell) each including one or more antibody variable domain encoding nucleic acids; (ii) performing PCR amplification of said antibody variable domain encoding nucleic acids of (i) using consensus sequence-specific primers to obtain amplification products (wherein said consensus sequence-specific primers bind to consensus sequences that are common to a plurality of genes within the genetic loci set, thereby generating a pool of amplification products); (iii) sequencing a plurality of said amplification products obtained in step (ii) in order to determine the relative proportion of each nucleotide at each position in a sequencing read; (iv) performing a sequence alignment between the sequencing read results of (iii) and the parental antibody variable domain encoding nucleic acid; (v) performing a sequence-identity/homology-based ranking of the antibody variable domain encoding nucleic acids in said sequence alignment with the parental antibody variable domain encoding nucleic acid being the perfect/template/reference sequence; and (vi) selecting the variant antibody variable domain encoding nucleic acid based on the sequence ranking of step (v), whereby the variant selected in step (vi) is selected so that the developability hot-spot is removed.
C12Q 1/6811 - Méthodes de sélection pour la production ou l’élaboration d’oligonucléotides spécifiques cibles ou de molécules de liaison
C12N 15/10 - Procédés pour l'isolement, la préparation ou la purification d'ADN ou d'ARN
G16B 15/00 - TIC spécialement adaptées à l’analyse de structures moléculaires bidimensionnelles ou tridimensionnelles, p. ex. relations structurelles ou fonctionnelles ou alignement de structures
G16B 20/20 - Détection d’allèles ou de variantes, p. ex. détection de polymorphisme d’un seul nucléotide
G16B 20/30 - Détection de sites de liaison ou de motifs
Herein is reported a polypeptide-linker-nucleic acid conjugate, wherein the linker comprises a 3-amino propanamide unit, a 2,6-diamino hexanoic acid amide unit, and a 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, wherein the polypeptide comprises a C-terminal lysine residue, and wherein the nucleic acid comprises an oxygen linked to a phosphorous atom of the oxidation state V at 5′ or 3′ terminus, wherein the 3-amino group of the 3-amino propanamide unit and the carboxy function of the lysine residue of the polypeptide are linked by/form an amide bond, the carboxy function of the 3-amino propanamide unit and the alpha amino group of the 2,6-diamino hexanoic acid amide unit are linked by/form an amide bond, the 6-amino group of the 2,6-diamino hexanoic acid amide unit is a nitrogen of the 1,2,3-triazole element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit, and the oxygen linked to the phosphorous atom of the nucleic acid is covalently linked to the cyclopropane element of the 1,4,5,5a,6,6a,7,8-octahydrocyclopropa[5,6]cycloocta[1,2-d]-1,2,3-triazole unit.
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
A method of assessing risk of mortality of a cancer patient comprising inputting cancer patient information to a model to generate a score indicative of risk of mortality of the cancer patient, wherein the patient information includes data corresponding to one or more cancer type-specific parameters, and data corresponding to each of the following parameters: level of albumin in serum or plasma, Eastern cooperative oncology group (ECOG) performance status, ratio of lymphocytes to leukocytes in blood, smoking status, age, TNM classification of malignant tumours stage, heart rate, chloride or sodium level in serum or plasma, urea nitrogen level in serum or plasma, gender, haemoglobin or haematocrit level in blood, aspartate aminotransferase enzymatic activity level in serum or plasma, and alanine aminotransferase enzymatic activity level in serum or plasma.
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
40.
COMPOSITIONS AND METHODS OF TREATING CHILDHOOD ONSET IDIOPATHIC NEPHROTIC SYNDROME
The present disclosure provides methods for treating childhood-onset idiopathic nephrotic syndrome (INS), or reducing risk and/or frequency of relapse from childhood-onset INS, in an individual that is greater than or equal to 2 years of age and less than or equal to 25 years of age. In some embodiments, the methods comprise administering to the individual an effective amount of obinutuzumab.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 31/138 - Aryloxyalkylamines, p. ex. propranolol, tamoxifène, phénoxybenzamine
A61K 31/167 - Amides, p. ex. acides hydroxamiques ayant des cycles aromatiques, p. ex. colchicine, aténolol, progabide ayant l'atome d'azote d'un groupe carboxamide lié directement au cycle aromatique, p. ex. lidocaïne, paracétamol
A61K 31/573 - Composés contenant des systèmes cycliques du cyclopenta[a]hydrophénanthrèneLeurs dérivés, p. ex. stéroïdes substitués en position 17 bêta par une chaîne à deux atomes de carbone, p. ex. prégnane ou progestérone substitués en position 21, p. ex. cortisone, dexaméthasone, prednisone ou aldostérone
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
Described herein are techniques of automatically extracting intervention responses of a subject from data associated with the subject. The system automatically determines time points (e.g., dates) indicating periods in which intervention responses were determined for subjects, and then uses the time points to identify datasets from which to extract intervention responses. The system extracts intervention responses of the subject from the identified datasets.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
42.
Methods for Increased Pipetting Surveillance Sensitivity and Systems for Performing the Same
Described herein are methods for pipetting liquids using a pipet comprising a disposable pipet tip having a filter using pressure data calibration for improved pipetting surveillance sensitivity and/or identifying defective pipets.
G01N 35/10 - Dispositifs pour transférer les échantillons vers, dans ou à partir de l'appareil d'analyse, p. ex. dispositifs d'aspiration, dispositifs d'injection
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
43.
METHOD OF INCREASING THE NUMBER OF USABLE CHANNELS IN MULTIPLEX PCR
Methods and systems are disclosed for performing a multiplex PCR to determine first and second target polynucleotides in a sample. The method includes (i) contacting the sample in a single container with a first probe oligonucleotide for the first target and with a second probe oligonucleotide for the second target. The first probe is labeled with a first label emitting a first label signal in a first channel, a first crosstalk signal in a second channel, and a second crosstalk signal in a third channel. The second probe is labeled with a second label emitting a second label signal in the third channel. The method further includes (ii) amplifying target polynucleotides by PCR, (iii) measuring a multitude of values in the second and third channels 10 over at least part of the amplification in step (ii), and (iv) determining the first target polynucleotide based on the values measured in step (iii).
C12Q 1/6818 - Tests d’hybridation caractérisés par les moyens de détection impliquant l’interaction de plusieurs marqueurs, p. ex. transfert d’énergie de résonance
C12Q 1/6825 - Détecteurs faisant intervenir la détection d’acides nucléiques
C12Q 1/686 - Réaction en chaine par polymérase [PCR]
G16B 25/20 - Réaction en chaîne par polyméraseConception d’amorces ou de sondesOptimisation de la sonde
44.
GRIPPING DEVICE CONFIGURED FOR GRIPPING AT LEAST ONE SLIDE
A gripping device configured for gripping at least one includes: at least one first gripping element including at least one first contact surface for gripping the slide; at least one second gripping element, wherein the second gripping element comprises at least one second contact surface for gripping the slide, wherein the second gripping element further comprises at least two protrusions which respectively extend essentially perpendicular to the second contact surface, wherein the at least two protrusions are located on opposing ends of the second contact surface, wherein the at least two protrusions are configured for centering the slide during gripping the slide via the gripping device; wherein the first gripping element and the second gripping element are linearly movable relative to one another, wherein the first contact surface of the first gripping element and the second contact surface of the second gripping element face each other.
B01L 9/00 - Dispositifs de supportDispositifs de serrage
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
45.
PORT DEVICE FOR INTRODUCING A LIQUID PHARMACEUTICAL COMPOUND INTO AN INTRAOCULAR SPACE
A port device (110) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The port device (110) comprises: a. a port body (120) providing at least one channel (122) fluidically connecting at least one extraocular port (124) of the port device (110) with at least one intraocular port (126) of the port device (110); b. at least one circumferential flange (128) for attaching the port body (120) to a rim of a scleral opening (118); and c. at least one valve (134) for controlling a flow of the pharmaceutical compound through the channel (122), the valve (134) comprising at least one valve member (136) having a default closed position preventing a flow of the pharmaceutical compound through the channel (122) and an open position permitting a flow of the pharmaceutical compound through the channel (122), wherein the valve member (136) is configured to be reversibly brought from the closed position into the open position by exerting an opening force. Further, a kit (150) for introducing at least one liquid pharmaceutical compound into at least one intraocular space (114) is proposed. The kit (150) comprises at least one port device (110) according to the present invention and at least one applicator device (146). The applicator device (146) is configured to engage with the port device (110). The applicator device (146) is configured to introduce the pharmaceutical compound into the intraocular space (114) through the port device (110).
A61F 9/00 - Procédés ou dispositifs pour le traitement des yeuxDispositifs pour mettre en place des verres de contactDispositifs pour corriger le strabismeAppareils pour guider les aveuglesDispositifs protecteurs pour les yeux, portés sur le corps ou dans la main
The present invention provides reversible fluorescent probes for cannabinoid receptor 1 ("CB1") having the general formula (I) wherein A and B are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.
C09B 23/08 - Colorants méthiniques ou polyméthiniques, p. ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre impair de groupes CH plus de trois groupes CH, p. ex. polycarbocyanines
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
C09B 69/00 - Colorants non prévus par un seul groupe de la présente sous-classe
C09B 69/10 - Colorants polymèresProduits de réactions de colorants avec des monomères ou avec des composés macromoléculaires
C09B 11/24 - Phtaléines contenant des groupes amine
C09B 23/10 - Colorants méthiniques ou polyméthiniques, p. ex. du type cyanine caractérisés par la chaîne méthinique contenant un nombre pair de groupes CH
In a first aspect, the invention relates to a filter element, preferably a blood filter element, comprising (A) a porous film, wherein the porous film comprises at least one film forming polymer and at least one film opener and is free of reactive agents; and (B) a porous support. A second aspect of the invention is directed to a process for preparing a filter element according to the first aspect. In a third aspect, the invention relates to a filter assembly, comprising (I) the filter element of the first aspect; and (II) a spreading member (C). A fourth aspect of the invention is directed to the filter element of the first aspect or the filter assembly of the third aspect, being prepared in the form of a sheet or stripe, preferably cuttable and/or punchable sheet or stripe, from which the filter element or the filter assembly is cut and/or punched in required dimensions, wherein the sheet or stripe has larger dimensions regarding length and width than the filter element or the filter assembly, allowing to cut and/or punch out at least one filter element or filter assembly, wherein in case of a filter assembly, the remaining part of spreading member (C) is optionally removed after cutting and/or punching. A fifth aspect of the invention is related to a method for preparing a filter element of the first aspect or the filter assembly of the third aspect. A sixth aspect of the invention relates to a test carrier system comprising the filter element of the first aspect, and a seventh aspect of the invention is related to a plasma separation and metering unit comprising the filter element of the first aspect. An eight aspect of the invention is directed to the use of the filter element of the first aspect or the plasma separation and metering unit of the seventh aspect for separation of blood plasma from whole blood.
B01D 39/16 - Autres substances filtrantes autoportantes en substance organique, p. ex. fibres synthétiques
B01D 67/00 - Procédés spécialement adaptés à la fabrication de membranes semi-perméables destinées aux procédés ou aux appareils de séparation
B01D 69/00 - Membranes semi-perméables destinées aux procédés ou aux appareils de séparation, caractérisées par leur forme, leur structure ou leurs propriétésProcédés spécialement adaptés à leur fabrication
B01L 9/00 - Dispositifs de supportDispositifs de serrage
G01N 33/49 - Analyse physique de matériau biologique de matériau biologique liquide de sang
G01N 33/52 - Utilisation de composés ou de compositions pour des recherches colorimétriques, spectrophotométriques ou fluorométriques, p. ex. utilisation de bandes de papier indicateur
A plasma separation and metering unit (110) is disclosed. The plasma separation and metering unit (110) comprises: • at least one housing (112), wherein the housing (112) comprises at least one receptacle (114) forming at least one sample port (116) for receiving at least one biological sample (168) comprising plasma (174); • at least one plasma separation element (118), wherein the plasma separation element (118) is received in the receptacle (114) of the housing (112), wherein the plasma separation element (118) comprises a sample application side (120) facing the sample port (116) and a plasma side (122) opposing the sample application side (120); and • at least one plasma metering capillary (124) extending from the housing (112), wherein an application end (126) of the plasma metering capillary (124) is fluidically connected to the plasma side (122) of the plasma separation element (118) and is configured for receiving the plasma separated from the biological sample (168) by the plasma separation element (118), wherein an outlet end (128) opposing the application end (126) of the plasma metering capillary (124) comprises an outlet opening (130), and wherein the plasma metering capillary (124) further comprises at least one lateral opening (148) in a capillary wall (132), the lateral opening (148) being located adjacent to the outlet end (128).
The present invention relates to lyo-ready biocompatible solutions and lyophilisates comprising an activeRNaseInh(-SH)n, kits comprising solutions and/or lyophilisates of the present invention and methods of producing solutions and/or lyophilisates of the present invention. The present invention further relates to the use of the herein disclosed solutions, kits and/or lyophilisates for inhibiting an RNase.
A61K 9/19 - Préparations médicinales caractérisées par un aspect particulier à l'état particulaire, p. ex. poudres lyophilisées
A61K 47/24 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant des atomes autres que des atomes de carbone, d'hydrogène, d'oxygène, d'halogènes, d'azote ou de soufre, p. ex. cyclométhicone ou phospholipides
A61K 38/17 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains
50.
MACROCYCLIC INHIBITORS OF KRAS FOR THE TREATMENT OF CANCER
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R7, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 513/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 31/504 - PyridazinesPyridazines hydrogénées formant une partie de systèmes cycliques pontés
A61K 31/506 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime non condensées et contenant d'autres hétérocycles
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
The problem to be solved is to provide a humanized anti-IL-6 receptor antibody MRA-containing formulation which is suitable for subcutaneous administration, wherein dimerization or deamidation is prevented during long-term storage. The present application is directed to a stable antibody-containing liquid formulation characterized by containing arginine and histidine buffer. A method of inhibiting deamidation or dimerization of such an antibody in a concentrated liquid formulation includes histidine buffer in the liquid formulation.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 9/00 - Préparations médicinales caractérisées par un aspect particulier
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 47/18 - AminesAmidesUréesComposés d’ammonium quaternaireAcides aminésOligopeptides ayant jusqu’à cinq acides aminés
A61K 47/20 - Composés organiques, p. ex. hydrocarbures naturels ou synthétiques, polyoléfines, huile minérale, gelée de pétrole ou ozocérite contenant du soufre, p. ex. sulfoxyde de diméthyle [DMSO], docusate, laurylsulfate de sodium ou acides aminosulfoniques
A61K 47/26 - Hydrates de carbone, p. ex. polyols ou sucres alcoolisés, sucres aminés, acides nucléiques, mono-, di- ou oligosaccharidesLeurs dérivés, p. ex. polysorbates, esters d’acide gras de sorbitan ou glycyrrhizine
The present disclosure is directed to the combination of a Fas axis antagonist, such as an anti-FasL antibody, and a Treg cell depletion therapy, for example an anti-CD25 antibody, optionally with a cancer vaccine, for use in the treatment of cancer.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present invention provides prognostic, predictive, and therapeutic methods for the treatment of rheumatoid arthritis (RA). The invention is based, at least in part, on the discovery that the expression level of one or more biomarkers described herein in a sample (e.g., a synovial tissue sample, a synovial fluid sample, or a combination thereof) from an individual having RA can be used in methods of determining whether an individual having RA is likely to exhibit disease progression, identifying an individual having RA who is likely to respond to a treatment including a disease modifying anti-rheumatic drug (DMARD), predicting responsiveness of an individual having RA to a treatment including a DMARD, selecting a therapy for an individual having RA, and treating an individual having RA, as well as related kits.
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
A61K 31/519 - PyrimidinesPyrimidines hydrogénées, p. ex. triméthoprime condensées en ortho ou en péri avec des hétérocycles
A61P 19/02 - Médicaments pour le traitement des troubles du squelette des troubles articulaires, p. ex. arthrites, arthroses
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
54.
METHOD FOR PRODUCING RECOMBINANT ADENO-ASSOCIATED VIRAL PARTICLES
Herein is reported a method for producing a recombinant adeno-associated viral particle (rAAVp) preparation comprising the steps of cultivating a mammalian cell comprising a gene encoding a non-adeno-associated-virus gene, which is operably linked to two AAV inverted terminal repeats (ITRs) (i.e. the non-adeno-associated virus gene is interspaced between the two AAV ITRs), a gene encoding the AAV Cap protein VP1 and/or VP3, a gene encoding the AAV Rep protein Rep78 or Rep68 and/or a gene encoding the AAV Rep protein Rep52 or Rep40, a gene encoding the adenoviral helper function E4orf6, and a gene encoding the adenoviral helper function E2A, recovering the rAAVp from the cell and/or the cultivation medium, and thereby producing the rAAVp preparation, whereby the cultivating of the mammalian cell is in the presence of at least one compound selected from one of the following groups of compounds the caspase inhibitor Q-VD-OPh and IDN6556, DNA damage response activation inducing substances, including ATM/ATR inducing substances, antiviral response inhibitors, AMPK activators, oxidative phosphorylation agents, inhibitors of κB kinase, dNTP synthesis enhancers, including co-factors and building blocks, and cell cycle modulators.
The disclosure provides for methods of assessing the risks (e.g., associated with a gene therapy for the treatment of DMD (e.g., delandistrogene moxeparvovec) comprising genotyping the DMD gene and analyzing the HLA type of a subject in need of the gene therapy (e.g., delandistrogene moxeparvovec).
Herein is reported a composition for the targeted delivery of large nucleic acids to the nucleus of a eukaryotic cell comprising non-covalent complexes of histones in form of assembled nucleosomes, a large nucleic acid, a hapten, and a bispecific binder that has a first binding specificity to the hapten and a second binding specificity to a cell-surface target present on the eukaryotic cell, wherein the histone and/or the nucleic acid is/are covalently bound/conjugated to the hapten, the histone and the large nucleic acid are associated (non-covalently) with each other/form a non-covalent complex, and the hapten and the bispecific binder are associated with each other/bound to each other by the first binding specificity of the bispecific binder.
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
C07K 16/44 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel non prévu ailleurs
C12N 15/113 - Acides nucléiques non codants modulant l'expression des gènes, p. ex. oligonucléotides anti-sens
57.
COMPUTER-IMPLEMENTED METHOD FOR DETECTING AT LEAST ONE ANALYTE IN A SAMPLE WITH A LASER DESORPTION MASS SPECTROMETER
A computer-implemented method for detecting at least one analyte in a sample with a laser desorption mass spectrometer (220) is disclosed. The method comprises:
a) at least one imaging step comprising imaging at least one reflective target (128) by using at least one imaging device (235), wherein the sample comprising the at least one analyte is applied to the reflective target (128);
b) at least one sample recognition step comprising localizing at least one sample region on the reflective target (128); and
c) at least one analyte detection step comprising detecting the at least one analyte in the sample using surface assisted laser desorption ionization mass spectrometry (SALDI-MS) with the laser desorption mass spectrometer (220), wherein laser irradiation is applied to the reflective target (128) by using at least one laser source (222) of the laser desorption mass spectrometer (220) such that at least one ion of the at least one analyte is generated which is detected by using at least one of a mass analyzing unit (224) or an ion-mobility spectrometry device of the laser desorption mass spectrometer (220), wherein the laser irradiation is steered on the localized sample region by using at least one control device (237).
The invention provides methods and compositions for treating bladder cancer (e.g., urothelial carcinoma (UC), including locally advanced or metastatic UC) in a subject, for example, by administering a treatment regimen that includes a PD-1 axis binding antagonist (e.g., atezolizumab) to the patient. Also provided are compositions (e.g., a PD-1 axis binding antagonist (e.g., atezolizumab) and/or a platinum-based chemotherapy (e.g., cisplatin or carboplatin and gemcitabine), pharmaceutical compositions thereof, kits thereof, and articles of manufacture thereof) for use in treating bladder cancer (e.g., UC, including locally advanced or metastatic UC) in a patient. Also provided are assays and methods for determining the presence and/or expression level of PD-L1 in a sample obtained from a patient and for labeling PD-L1 in a sample obtained from a patient.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61P 13/10 - Médicaments pour le traitement des troubles du système urinaire de la vessie
A method may include training a machine learning model to determine a first pharmacokinetic parameter and a second pharmacokinetic parameter for a molecule. The machine learning model may be trained by at least determining, based at least on an input including one or more pharmacokinetic models associated with the molecule, a first value of the first pharmacokinetic parameter, determining, based at least on the input, a second value of the first pharmacokinetic parameter, and determining, based at least on the first value and the second value of the first pharmacokinetic parameter, a third value of the second pharmacokinetic parameter. The method may also include applying the trained machine learning model to determine, based at least on a sparsely sampled pharmacokinetic model associated with the molecule, the first pharmacokinetic parameter and/or the second pharmacokinetic parameter. Related methods and articles of manufacture are also disclosed.
G16B 5/00 - TIC spécialement adaptées à la modélisation ou aux simulations dans la biologie des systèmes, p. ex. réseaux de régulation génétique, réseaux d’interaction entre protéines ou réseaux métaboliques
A method may include extracting a plurality of features for each cell depicted in an image. A biomarker identification model may be applied to determine, based on the features associated with each cell, whether the cell is associated with various biomarkers. A set of probabilities for each cell in the population of cells may be determined based on an output of the biomarker identification model. The set of probabilities may include, for each biomarker, a probability of a corresponding cell being associated with the biomarker. One or more subsets of cells, each of which corresponding to a different cellular phenotype, may be identified based on the set of probabilities associated with each cell. A feature set associated with each subset of cells may be identified as being indicative of a probability of a cell being associated with a corresponding phenotype. Related systems and computer program products are also provided.
G16B 20/00 - TIC spécialement adaptées à la génomique ou protéomique fonctionnelle, p. ex. corrélations génotype-phénotype
G06V 10/40 - Extraction de caractéristiques d’images ou de vidéos
G06V 20/69 - Objets microscopiques, p. ex. cellules biologiques ou pièces cellulaires
G16B 40/00 - TIC spécialement adaptées aux biostatistiquesTIC spécialement adaptées à l’apprentissage automatique ou à l’exploration de données liées à la bio-informatique, p. ex. extraction de connaissances ou détection de motifs
The present invention relates to to a computer-implemented method, a computer program, a non-transitory computer-readable storage medium, including instructions, a data processing device, and a health management device for predicting a potential effect and/or future concentration of an analyte in a bodily fluid as well as relates to a health management system for health management of a chronic disease. In order to improve health management, a subject is notified about an at least one upcoming future event and its potential effect on the analyte concentration in the bodily fluid of the subject.
G16H 20/17 - TIC spécialement adaptées aux thérapies ou aux plans d’amélioration de la santé, p. ex. pour manier les prescriptions, orienter la thérapie ou surveiller l’observance par les patients concernant des médicaments ou des médications, p. ex. pour s’assurer de l’administration correcte aux patients administrés par perfusion ou injection
G16H 40/63 - TIC spécialement adaptées à la gestion ou à l’administration de ressources ou d’établissements de santéTIC spécialement adaptées à la gestion ou au fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement d’équipement ou de dispositifs médicaux pour le fonctionnement local
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
62.
TEMPERATURE MEASURING ASSEMBLY, ATTACHMENT AND SYSTEM FOR DETERMINING A TEMPERATURE INSIDE A MEDICAL CONTAINER, METHOD OF TEMPERATURE MONITORING, PROCESS VALIDATION AND/OR EQUIPMENT QUALIFICATION
The present invention relates to a temperature measuring assembly (100) for determining a temperature inside a medical container (20), the medical container (20) having a hollow body (21) with an outer body wall (22) and a body opening (23). The temperature measuring assembly (100) comprises a temperature sensor (40) comprising at least one detector element (42) having a temperature sensing portion (41), and a sensor holder (30) holding the temperature sensor (40). The sensor holder (30) is configured to be installed on the medical container (20) such that it extends through the body opening (23) into the interior of the hollow body (21) and that the temperature sensing portion (41) of the at least one detector element (42) is positioned inside the hollow body (21) at or close to the outer body wall (22) of the hollow body (21). The present invention also relates to a temperature measuring attachment (110) and a temperature measuring system (12) for determining a temperature inside a medical container (20), as well as to a method of temperature monitoring, process validation and/or equipment qualification in connection with handling temperature-controlled medical products using such a temperature measuring assembly (100), attachment (110) or system (120).
The present invention relates to compounds of formula (I),
The present invention relates to compounds of formula (I),
wherein R1 to R6, A1 and A2 are as described herein, and their pharmaceutically acceptable salt thereof, and compositions including the compounds and methods of using the compounds.
C07D 515/22 - Composés hétérocycliques contenant dans le système condensé au moins un hétérocycle comportant des atomes d'azote, d'oxygène et de soufre comme uniques hétéro-atomes du cycle, non prévus dans les groupes , ou dans lesquels le système condensé contient au moins quatre hétérocycles
A61K 31/504 - PyridazinesPyridazines hydrogénées formant une partie de systèmes cycliques pontés
A61K 31/5377 - 1,4-Oxazines, p. ex. morpholine non condensées et contenant d'autres hétérocycles, p. ex. timolol
65.
DOUBLE-STRANDED RNA MOLECULE FOR ADMINISTRATION TO THE EYE
The present invention relates to double-stranded RNA molecules conjugated to at least one conjugate moiety for topical administration to the eye, and pharmaceutical compositions thereof. The double-stranded RNA molecules are complementary, such as fully complementary, to targets expressed in the eye, and are capable of inhibiting expression of targets expressed in the eye. The double-stranded RNA molecules can be used in the treatment of conditions and diseases of the eye.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
A61K 45/06 - Mélanges d'ingrédients actifs sans caractérisation chimique, p. ex. composés antiphlogistiques et pour le cœur
The present invention relates to the treatment of subjects having a CD20-positive cell proliferative disorder. More specifically, the invention pertains to the treatment of subjects having a CD20-positive cell proliferative disorder by administering a combination of mosunetuzumab and polatuzumab vedotin.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
The present disclosure relates to the simultaneous imaging of nucleic acids and proteins in a sample. In particular, the present disclosure provides compositions, methods, systems and kits for imaging at least one target protein and at least one target nucleic acid in a single sample.
C12Q 1/6876 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
69.
METHODS AND COMPOSITIONS COMPRISING PURIFIED RECOMBINANT POLYPEPTIDES
Purified recombinant polypeptides isolated from Chinese hamster ovary host cells, including antibodies, such as therapeutic antibodies, and methods of making and using such polypeptides are provided.
C07K 16/24 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des cytokines, des lymphokines ou des interférons
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
Hbb]pyrazine compound of formula (I), or a stereoisomer thereof: Formula (I), or a pharmaceutically acceptable salt thereof; and compounds prepared by these processes.
C07D 491/107 - Systèmes condensés en spiro avec un seul atome d'oxygène comme hétéro-atome du cycle contenant de l'oxygène
C07D 519/00 - Composés hétérocycliques contenant plusieurs systèmes de plusieurs hétérocycles déterminants condensés entre eux ou condensés avec un système carbocyclique commun non prévus dans les groupes ou
The present invention provides antibodies specifically binding to Pepsinogen A and compositions and kits comprising such antibodies. Furthermore, provided are polynucleotides encoding such antibodies, host cells expressing said antibodies, methods of producing such antibodies and diagnostic methods using such antibodies.
The present invention discloses a new gene fusion which is characteristic for Non- small-cell lung cancer cells and can this be used for specific detection for of Non- small-cell lung tumors.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
74.
METHODS AND MATERIALS FOR MEASURING COMPLEMENT ACTIVATION
C07K 7/06 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 5 à 11 amino-acides
A61K 38/00 - Préparations médicinales contenant des peptides
C07K 7/08 - Peptides linéaires ne contenant que des liaisons peptidiques normales ayant de 12 à 20 amino-acides
C07K 14/47 - Peptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'animauxPeptides ayant plus de 20 amino-acidesGastrinesSomatostatinesMélanotropinesLeurs dérivés provenant d'humains provenant de vertébrés provenant de mammifères
G01N 33/564 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour complexes immunologiques préexistants ou maladies auto-immunes
75.
DATA-INDEPENDENT ACQUISITION (DIA) FOR MASS SPECTROMETRIC ANALYSIS OF MHC PEPTIDES
e.g.e.g., a patient sample). In some instances, for example, the methods can comprise: predicting, using one or more machine-learning models, an MHC allele-specific mass spectral library for the sample; performing a mass spectrometric analysis of peptides extracted from the sample using data-independent acquisition (DIA) to generate mass spectral data for the peptides; and performing a spectral library search using the mass spectral data for the peptides and the predicted MHC allele-specific mass spectral library for the sample to identify at least one MHC peptide present in the sample.
G16B 15/30 - Ciblage de médicament à l’aide de données structurellesPrévision d’amarrage ou de liaison moléculaire
G16B 40/10 - Traitement du signal, p. ex. de spectrométrie de masse ou de réaction en chaîne par polymérase
A61K 39/00 - Préparations médicinales contenant des antigènes ou des anticorps
C12Q 1/6881 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour le typage de tissu ou de cellule, p. ex. sondes d’antigène leucocytaire humain [HLA]
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 33/569 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet pour micro-organismes, p. ex. protozoaires, bactéries, virus
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
Produits et services
Chemical preparations for scientific purposes, other than
for medical or veterinary use; biological preparations,
other than for medical or veterinary purposes; biochemical
preparations for scientific purposes; diagnostic reagents
for scientific or research use; reagents for use in
scientific apparatus for chemical or biological analysis;
chemical preparations for analyses in laboratories, other
than for medical or veterinary purposes; nucleic acids for
scientific purposes; diagnostic reagents for in vitro use in
biochemistry, clinical chemistry and microbiology; chemical
reagents for use in genetic research.
77.
METHOD TO ANALYZE AND OPTIMIZE GENE EDITING MODULES AND DELIVERY APPROACHES
Herein is reported a method for determining the introduction of a nucleic acid into the genome of a mammalian cell, whereby the mammalian cell comprises one or two transcriptionally active alleles of a DPH1, DPH2, DPH4 and/or DPH5 gene, comprising the steps of transfecting the mammalian cell with one or more plasmids comprising the nucleic acid to be introduced, and the elements required for gene editing of said DPH gene, cultivating the transfected cell in the presence of a DPH gene transcription sensitive toxin, and thereby determining the introduction of a nucleic acid into the genome of the mammalian cell if the transfected cells is viable in the presence of the toxin.
C12N 15/11 - Fragments d'ADN ou d'ARNLeurs formes modifiées
C12N 15/63 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression
C12N 15/65 - Introduction de matériel génétique étranger utilisant des vecteursVecteurs Utilisation d'hôtes pour ceux-ciRégulation de l'expression utilisant des marqueurs
C12N 15/90 - Introduction stable d'ADN étranger dans le chromosome
C12Q 1/02 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des micro-organismes viables
C12Q 1/6827 - Tests d’hybridation pour la détection de mutation ou de polymorphisme
78.
MACHINE LEARNING ENABLED PREDICTION OF MOLECULAR STRUCTURES AND PROPERTIES
A method may include receiving a molecular structure file specifying an initial three-dimensional structure of a molecule. A representation of the molecule may be determined based on the molecular structure file. For example, the representation of the molecule may include a plurality of coarse-grained nodes, each corresponding to a structural body of two or more atoms (e.g., heavy atoms) forming an amino acid residue in the molecule. Alternatively, the representation of the molecule may include, for each residue in the molecule, a plurality of frames specifying a geometric state of the backbone of the residue and one or more torsion angles in the sidechain of the residue. A design computation model may be applied to determine a three-dimensional structure of the molecule by at least modifying the representation of the molecule. The three-dimensional structure may be associated with a desirable property and/or be configured for a downstream task.
G16B 45/00 - TIC spécialement adaptées à la visualisation de données liées à la bio-informatique, p. ex. affichage de cartes ou de réseaux
79.
IN VITRO DIAGNOSTIC TEST SYSTEM, IVD TEST APPARATUS AND A METHOD OF PERFORMING A MULTIPLEXED DIAGNOSTIC ASSAY AT AN IMPROVED DEGREE OF EFFICIENCY AND ECO-FRIENDLINESS
The invention allows an increased throughput of diagnostic assays and doubles, triples or even further increases the number of assays per cartridge and may therefore be considered as very environmental- and eco-friendly. At the same time, multiple potentially life-saving test results may be provided for one or more patients. The invention relates to an In Vitro diagnostic (IVD) test system (1a, 1b) for performing a multiplexed diagnostic assay, wherein the IVD test system (1a, 1b) comprises: a test carrier (2) comprising a sample application port (3) configured to receive a sample fluid (30); a test zone (4) comprising a shared recessed assay membrane area (4a) and a sample release port (4b) for releasing at least one portion (30, 30a) of the sample fluid (30) to the shared recessed assay membrane area (4a); and a microfluid sample channel system (5) configured to guide the at least one portion (30, 30a) of the sample fluid (30) from the sample application port (3) to the sample release port (4b); the IVD test system (1a, 1b) further comprising: a first assay membrane (6) positioned in the shared recessed assay membrane area (4a) and configured to receive a first part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one first analyte (31a) in the first part of the at least one portion (30, 30a) of the sample fluid (30); and a second assay membrane (7) positioned in the shared recessed assay membrane area (4a) next to the first assay membrane (6) and configured to receive a second part of the at least one portion (30, 30a) of the sample fluid (30) from the sample release port (4b) and to indicate at least one second analyte (31b) in the second part of the at least one portion (30, 30a) of the sample fluid (30) and/or to indicate the at least one first analyte (31a) in the second part of the at least one portion (30, 30a) of the sample fluid (30) in a different sensitivity range as the first assay membrane (6).
B01L 3/00 - Récipients ou ustensiles pour laboratoires, p. ex. verrerie de laboratoireCompte-gouttes
G01N 33/00 - Recherche ou analyse des matériaux par des méthodes spécifiques non couvertes par les groupes
G01N 35/00 - Analyse automatique non limitée à des procédés ou à des matériaux spécifiés dans un seul des groupes Manipulation de matériaux à cet effet
G01N 33/70 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir la créatine ou la créatinine
G01N 30/00 - Recherche ou analyse de matériaux par séparation en constituants utilisant l'adsorption, l'absorption ou des phénomènes similaires ou utilisant l'échange d'ions, p. ex. la chromatographie
G01N 33/543 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet avec un support insoluble pour l'immobilisation de composés immunochimiques
G01N 33/58 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des substances marquées
80.
TWO NOVEL FUSION TRANSCRIPTS FOR EARLY DETECTION OF NON-SMALL-CELL LUNG CANCER (NSCLC)
The present invention provides a new gene fusion of TPTE2 and MRPS31P2 which is characteristic for Non-small-cell lung cancer cells and can be used for specific detection of Non-small-cell lung tumors.
C12Q 1/6886 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique pour le cancer
e.g.e.g.e.g., tuberculosis, leprosy, nontuberculous mycobacterial infections, or a combination thereof). Pharmaceutical compositions comprising said compounds are also provided.
C07D 413/12 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant deux hétérocycles liés par une chaîne contenant des hétéro-atomes comme chaînons
C07D 413/14 - Composés hétérocycliques contenant plusieurs hétérocycles, au moins un cycle comportant des atomes d'azote et d'oxygène comme uniques hétéro-atomes du cycle contenant au moins trois hétérocycles
A61K 31/436 - Composés hétérocycliques ayant l'azote comme hétéro-atome d'un cycle, p. ex. guanéthidine ou rifamycines ayant des cycles à six chaînons avec un azote comme seul hétéro-atome d'un cycle condensés en ortho ou en péri avec des systèmes hétérocycliques le système hétérocyclique contenant un cycle à six chaînons ayant l'oxygène comme hétéro-atome du cycle, p. ex. rapamycine
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
chemical, biological and biochemical preparations for scientific and research purposes; chemical substances for analyses in laboratories, not for medical or veterinary purposes; diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology research; biochemical preparations, namely, recombinant human enzymes, for scientific and research purposes; chemical reagents for molecular biology, not for medical or veterinary use chemical, biological and biochemical preparations for medical purposes; in vitro diagnostic reagents for medical purposes; chemical substances for analyses in laboratories for medical purposes; reagents for in-vitro laboratory use for medical purposes; chemical preparations containing enzymes for medical purposes; biochemical preparations, namely, recombinant human enzymes for medical purposes
The present invention provides methods to prevent the formation of visible particles in aqueous protein formulations, as well as compositions and pharmaceutical products obtained with said method.
The present invention provides therapeutic, diagnostic, and prognostic methods for cancer. The invention provides methods of treating a cancer, methods of determining whether an individual having a cancer is likely to respond to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of predicting responsiveness of an individual having a cancer to a treatment including an immune checkpoint inhibitor (e.g., a PD-L1 axis binding antagonist), methods of selecting a therapy for an individual having a cancer, methods of providing a prognosis for an individual having a cancer, and methods of monitoring a response of an individual having a cancer, based on a blood tumor mutational burden (bTMB) score or a maximum somatic allele frequency (MSAF) from a sample (e.g., a whole blood sample, a plasma sample, a serum sample, or a combination thereof) from the individual.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
C12Q 1/68 - Procédés de mesure ou de test faisant intervenir des enzymes, des acides nucléiques ou des micro-organismesCompositions à cet effetProcédés pour préparer ces compositions faisant intervenir des acides nucléiques
C12Q 1/6883 - Produits d’acides nucléiques utilisés dans l’analyse d’acides nucléiques, p. ex. amorces ou sondes pour les maladies provoquées par des altérations du matériel génétique
G06F 16/28 - Bases de données caractérisées par leurs modèles, p. ex. des modèles relationnels ou objet
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 50/30 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le calcul des indices de santéTIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour l’évaluation des risques pour la santé d’une personne
G16H 50/50 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la simulation ou la modélisation des troubles médicaux
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
86.
CROSS-MODALITY PIXEL ALIGNMENT AND CELL-TO-CELL REGISTRATION ACROSS VARIOUS IMAGING MODALITIES
A method implemented by one or more computer devices includes receiving a plurality of images of a set of tissue cells, the plurality of images comprising a first image including a first visualization modality and a second image including a second visualization modality. The method includes identifying a first tissue cell of the set of tissue cells in the first image and the first tissue cell in the second image, and performing a cell-to-cell registration process based on the first tissue cell identified in the first image and the first tissue cell identified in the second image. The cell-to-cell registration process includes matching of the first tissue cell identified in the first image to the first tissue cell identified in the second image. The method includes classifying the first tissue cell into a phenotype based on the cell-to-cell registration process, the phenotype partially indicative of a disease pathology.
G01N 33/53 - Tests immunologiquesTests faisant intervenir la formation de liaisons biospécifiquesMatériaux à cet effet
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
87.
SPACETIME ATTENTION FOR CLINICAL OUTCOME PREDICTION
A disease prognosis model to may be trained to determine the clinical outcome of a disease based on longitudinal data including a health record for each timepoint in a sequence of timepoints. The disease prognosis model may include a recurrent neural network trained to extract, from each health record, a feature set representative of local dependencies present within the health record. The disease prognosis model may include a spacetime attention trained to determine an importance of each feature in the feature set at each timepoint in the sequence of timepoints. The disease prognosis model may include a feedforward neural network trained to determine, based on the importance of each feature in the feature set at each time point in the sequence of timepoints, the clinical outcome of the disease. The trained disease prognosis model may be applied to determine the clinical outcome of the disease for one or more patients.
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
G16H 10/60 - TIC spécialement adaptées au maniement ou au traitement des données médicales ou de soins de santé relatives aux patients pour des données spécifiques de patients, p. ex. pour des dossiers électroniques de patients
G16H 50/80 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour la détection, le suivi ou la modélisation d’épidémies ou des pandémies, p. ex. de la grippe
88.
TARGET ENRICHMENT BY UNIDIRECTIONAL DUAL PROBE PRIMER EXTENSION
The present disclosure provides a method for enrichment of at least one target nucleic acid in a library of nucleic acids. A first oligonucleotide is hybridized to a target nucleic acid in library of nucleic acids having first and second adapters. The hybridized first oligonucleotide is extended with a first polymerase, thereby producing a first primer extension complex including the target nucleic acid and the extended first oligonucleotide. The first primer extension complex is captured, enriched relative to the library of nucleic acids, and a second oligonucleotide is hybridized to the target nucleic acid. The hybridized second oligonucleotide is extended with a second polymerase, thereby producing a second primer extension complex including the target nucleic acid and the extended second oligonucleotide and further liberating the extended first oligonucleotide from the first primer extension complex.
A biomedical knowledge graph system includes a computer database of records comprising nodes of biomedical entities and connections between the entities representing biomedical relationships. One or more processors are configured to extract data from a plurality of data sources and determine biomedical entities and relationships between the entities based on analyzing the data, including searching for predetermined identifiers or patterns in the data. Based on the determined biomedical entities, each biomedical entity is assigned to a cluster of biomedical entity types and a context is identified for each of the entities. Based on the identified context and type of the biomedical entity, records of nodes and connections between nodes are incorporated into the knowledge graph, the nodes representing biomedical entities and the connections representing biomedical relationships between the entities structured according to the predefined schema.
G16H 50/70 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour extraire des données médicales, p. ex. pour analyser les cas antérieurs d’autres patients
Computer-implemented methods of providing a clinical predictor tool are described, comprising: obtaining training data comprising, for each of a plurality of patients, values for a plurality of clinical variables comprising a variable indicative of a diagnosis or prognosis and one or more further clinical variables; and training a clinical predictor model to predict the variable indicative of a diagnosis or prognosis using said training data, wherein obtaining the training data comprises obtaining synthetic clinical data comprising values for a plurality of clinical variables for one or more patients by obtaining a directed acyclic graph (DAG) edges corresponding to conditional dependence relationships inferred from real clinical data comprising values for the plurality of clinical variables for a plurality of patients, and obtaining values for each node of the DAG using a machine learning model and multivariate conditional probability table. Computer-implemented methods of obtaining synthetic clinical data are also described.
G06N 5/01 - Techniques de recherche dynamiqueHeuristiquesArbres dynamiquesSéparation et évaluation
G16H 50/20 - TIC spécialement adaptées au diagnostic médical, à la simulation médicale ou à l’extraction de données médicalesTIC spécialement adaptées à la détection, au suivi ou à la modélisation d’épidémies ou de pandémies pour le diagnostic assisté par ordinateur, p. ex. basé sur des systèmes experts médicaux
91.
PREDICTING TILE-LEVEL CLASS LABELS FOR HISTOPATHOLOGY IMAGES
A method implemented by one or more computer devices includes providing weakly-supervised neural networks for analysis of histopathology images. The method includes accessing a histopathology image including a slide-level class label. The method includes extracting a plurality of regions of pixels of the histopathology image at a plurality of magnifications. For each of the extracted plurality of regions of pixels, the method further includes inputting the region of pixels into a machine-learning model trained to generate a prediction of a class label for the region of pixels based on the region of pixels and the slide-level class label and outputting the prediction of the class label for the region of pixels. The method includes generating a prediction of one or more tile-level class labels for the histopathology image based on the predictions of class labels for each of the extracted plurality of regions of pixels.
The invention concerns methods and means for preventing the reduction of disulfide bonds during the recombinant production of disulfide-containing polypeptides. In particular, the invention concerns the prevention of disulfide bond reduction during harvesting of disulfide-containing polypeptides, including antibodies, from recombinant host cell cultures.
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A61K 39/395 - AnticorpsImmunoglobulinesImmunsérum, p. ex. sérum antilymphocitaire
C07K 16/18 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains
C07K 16/40 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre des enzymes
G01N 33/68 - Analyse chimique de matériau biologique, p. ex. de sang ou d'urineTest par des méthodes faisant intervenir la formation de liaisons biospécifiques par ligandsTest immunologique faisant intervenir des protéines, peptides ou amino-acides
94.
Biomolecule Fitness Inference Using Machine Learning for Drug Discovery with Directed Evolution
In one embodiment, a method includes accessing a biomolecule representation of a first biomolecule and processing the biomolecule representation by a machine-learning model trained using sequencing time-series data. The sequencing time-series data was obtained from directed evolution of a population of biomolecules over multiple enrichment rounds where the population of biomolecules in each enrichment round was a unique set of biomolecules with respect to each other enrichment round. The sequencing time-series data for each enrichment round comprises a biomolecule frequency of each biomolecule of the population of biomolecules in the respective enrichment round. The training comprises learning inferred fitness scores of the population of biomolecules for each enrichment round by predicting biomolecule frequencies of the population of biomolecules in the respective enrichment round given biomolecule frequencies of the population of biomolecules in prior enrichment rounds. The method further includes outputting an inferred fitness score for the first biomolecule.
The present invention relates to the field of polypeptide conjugates, more in particular to conjugates comprising a polypeptide, a nucleic acid and a linker, wherein the conjugation involves a click chemistry between an organic azide and dibenzocyclooctine (DBCO) derivatives. The invention relates as well to methods to obtain such conjugates, as well as to their use in the treatment of a neurological disease, a brain disease, or cancer.
A61K 47/64 - Conjugués médicament-peptide, médicament-protéine ou médicament-acide polyaminé, c.-à-d. l’agent de modification étant un peptide, une protéine ou un acide polyaminé lié par covalence ou complexé à un agent thérapeutiquement actif
A61K 47/65 - Séquences de liaison, liants ou bras-espaceurs peptidiques, p. ex. séquences de liaison peptidiques vulnérable aux protéases
A61K 47/68 - Préparations médicinales caractérisées par les ingrédients non actifs utilisés, p. ex. les supports ou les additifs inertesAgents de ciblage ou de modification chimiquement liés à l’ingrédient actif l’ingrédient non actif étant chimiquement lié à l’ingrédient actif, p. ex. conjugués polymère-médicament l’ingrédient non actif étant un agent de modification l’agent de modification étant un anticorps, une immunoglobuline ou son fragment, p. ex. un fragment Fc
C07K 16/28 - Immunoglobulines, p. ex. anticorps monoclonaux ou polyclonaux contre du matériel provenant d'animaux ou d'humains contre des récepteurs, des antigènes de surface cellulaire ou des déterminants de surface cellulaire
A computer-implemented method for controlling a mass spectrometry analyzer system (110) for analysis of an analyte of interest is proposed. The mass spectrometry analyzer system (110) comprises at least one sample preparation unit, at least one liquid chromatography (LC) unit and at least one mass spectrometer (MS) analyzer unit. The method comprises automatically performing the following steps a) providing at least one experimental plan for at least one unit of the mass spectrometry analyzer system, wherein the experimental plan comprises at least one initial parameter set considering initial knowledge of at least one knowledge database, wherein the initial parameter set comprises at least one control parameter used for performing at least one measurement for analysis of the analyte of interest on said unit, wherein the experimental plan comprises scanning at least partially a parameter space of the control parameter; b) transferring the experimental plan into control instructions for said unit; c) executing the control instructions on said unit, thereby performing at least one measurement in accordance with the experimental plan and obtaining at least one measurement result; d) evaluating the measurement result obtained in step c), wherein the evaluating comprises optimizing the initial parameter set in view of the measurement result, thereby determining an optimized parameter set; and e) storing and/or updating the optimized parameter set in the knowledge database.
01 - Produits chimiques destinés à l'industrie, aux sciences ainsi qu'à l'agriculture
05 - Produits pharmaceutiques, vétérinaires et hygièniques
Produits et services
Diagnostic reagents for in vitro use in biochemistry, clinical chemistry and microbiology; Biological preparations, other than for medical or veterinary purposes; Biochemical preparations for scientific purposes; Diagnostic reagents for scientific or research use; Chemical substances for analyses in laboratories, other than for medical or veterinary purposes; Chemical preparations for scientific purposes, other than for medical or veterinary use. Chemical preparations for medical purposes; Biochemical preparations for medical use; In vitro diagnostic preparations for medical use; Diagnostic reagents for medical use; Reagents for in-vitro laboratory use [for medical purposes]; Biological preparations for medical purposes.
09 - Appareils et instruments scientifiques et électriques
Produits et services
(1) Bio-sensors; biochip sensors; barcode readers; bar code printers; portable scanners; radio-frequency identification (RFID) tags; interfaces for computers; electronic docking stations; application software for cloud computing services; cases for tablet computers; cases for data storage devices; computer software relating to the medical field; computer software for use in medical decision support systems; workflow management system software; software as a medical device [SaMD], downloadable; application software for mobile devices.
09 - Appareils et instruments scientifiques et électriques
25 - Vêtements; chaussures; chapellerie
28 - Jeux, jouets, articles de sport
Produits et services
Vêtements de protection contre les accidents; dispositifs électroniques de déclenchement de matériel de sécurité et de matériel de protection contre les accidents; renforts de protection pour le dos, le thorax, les épaules, les coudes et les genoux, pour la protection contre les accidents; vêtements, chaussures, gants et casques de protection; lunettes, lunettes de soleil, montures de lunettes, verres de lunettes et étuis à lunettes; visières anti-éblouissantes. Casques de protection pour la pratique des deux, trois ou quatre roues et pour la pratique des sports mécaniques deux, trois ou quatre roues; visières de casques; parties de vêtements de protection contre les accidents ou les blessures à savoir rembourrages de protection et de sécurité pour la pratique des deux, trois ou quatre roues; protèges genoux et protèges coudes contre les accidents ou les blessures pour la pratique des deux, trois ou quatre roues. Vêtements, vêtements en cuir; vêtements de sport, vêtements d’équitation; blousons et vestes textiles, gilets, sweatshirts, t-shirts, pantalons; chemises; ceintures (habillement); fourrures (vêtements); gants (habillement); foulards; chapellerie; bonneterie; casquettes; bonnets; bandanas; chaussettes; chaussons; chaussures; chaussures de sport, sous-vêtements. Rembourrages de protection pour la pratique de sports, rembourrages de protection en tant que parties d'habillement de sport, protège-hanches, protège-dos pour le sport, dispositifs de protection dorsale, ceintures protège-taille pour le sport, protège-tibias, protège-chevilles, protège-genoux, protège-jambes pour le sport, protège-coudes, protège-mains, protège-poignets, protèges-épaules (articles de sport), protège-cou pour le sport, tenues de protection (pour le sport), gants de protection (pour le sport), sacs conçus pour le transport d'équipements de sport.
